Engineering Cellular Shielding to Reduce Allogeneic Rejection

• Targeting genes that drive immune mediated rejection to protect therapeutic cells
• Applying multi gene knockout approaches to combat complex immune responses and reduce rejection risk
• Evaluating the impact of cellular shielding on long term persistence to demonstrate sustained efficacy and improved patient outcomes

Speakers:

Tom Wickham

Chief Scientific Officer

GentiBio